Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. LONDON (AP) — The ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...